Browsing: Pharmaceuticals

This is a paid press release. Contact the press release distributor directly with any enquiries.

WASHINGTON, July 7, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda’s investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), a rare, serious, and progressive inherited neurological disorder. The designation…

The $10 Billion Acquisition Is Set, as Vertex Pharmaceuticals Bets on a New Blue Ocean in Rare Endocrine Diseases | NAI 500